The company has modified contract with the US Department of Health and Human Services for the development and supply of Anthrax Immune Globulin Intravenous (AIGIV).
The modification extends to 2016 to conduct additional activities in support of obtaining licensure for AIGIV and is expected togenerate up to approximately $16.5m in additional revenue for Cangene over the next four years.
Thes AIGIV, a hyperimmune antibody product specific for Bacillus anthracis bacteria, was developed to treat inhalational anthrax.
Cangene president and CEO John Sedor said, "Cangene will continue to pursue opportunities to leverage our core competencies in biodefence while maintaining a focus on our commercial product business and expanding our pipeline."
As part of the new contract with the Centers for Disease Control and Prevention, Cangene will supply Vaccinia Immune Globulin Intravenous (VIGIV) into the US Strategic National Stockpile, and provide services to support licensure maintenance activities for the product.
The contract is expected to generate up to approximately $9.8m in additional revenue for Cangene over an 18 month period.
VIGIV is a hyperimmune product to be used in treating and preventing certain types of severe complications that may be associated with smallpox vaccination, and is considered an important component of smallpox vaccination programs.